Fluperlapine

Fluperlapine is a drug that was developed by Janssen Pharmaceutica in the 1970s. It is classified as an atypical antipsychotic and antidepressant. However, it was never marketed.

Pharmacology

Fluperlapine is known to bind to the serotonin and dopamine receptors. It has high affinity for the 5-HT2A, 5-HT2C, D1, and D2 receptors. It also has moderate affinity for the 5-HT1A, 5-HT6, and 5-HT7 receptors.

Clinical Trials

Fluperlapine has been tested in clinical trials for the treatment of schizophrenia and depression. However, it was found to have a high incidence of side effects, including sedation and weight gain, which led to its discontinuation.

See Also

• Atypical antipsychotic
• Antidepressant
• Janssen Pharmaceutica

Fluperlapine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski